BioAge Labs (BIOA) Debt Ratio (2023 - 2026)

BioAge Labs (BIOA) posted Debt Ratio of 0.0 for Q1 2026, down 67.54% sequentially from 0.01 in Q4 2025, and down 85.8% YoY from 0.02 in Q1 2025.

BioAge Labs (BIOA) Debt Ratio (2023 - 2026) Analysis & Trends

BioAge Labs has reported Debt Ratio for 4 years, with the latest figure at 0.0 in Q1 2026.

Quarterly Debt Ratio fell 85.8% year-over-year to 0.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0 (down 85.8% YoY) and the FY2025 annual result came in at 0.01, down 62.16% from the prior year.
Debt Ratio declined to 0.0 in Q1 2026 per BIOA's latest filing, from 0.01 in the prior quarter.
Over five years, Debt Ratio peaked at 0.55 in Q4 2023 and troughed at 0.0 in Q1 2026.
A 4-year average of 0.08 and a median of 0.02 in 2025 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2024 and 2025: Debt Ratio slumped 95.67% in 2024, then sank 54.1% in 2025.
Over 4 years, Debt Ratio stood at 0.55 in 2023, then plunged by 95.67% to 0.02 in 2024, then plunged by 62.16% to 0.01 in 2025, then slumped by 67.54% to 0.0 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.0, 0.01, and 0.01 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	0.42
3	Zoetis	31.53 Bn	29.85 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn	0.32
5	United Therapeutics	22.13 Bn	19.47 Bn	683.80 Mn	-
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.53 Bn	15.14 Bn	935.80 Mn	-
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.13 Bn	9.97 Bn	-	0.12
10	BioAge Labs	437.85 Mn	437.85 Mn	-14.23 Mn	-

Download Data